These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16574416)

  • 1. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.
    Foloppe N; Fisher LM; Howes R; Potter A; Robertson AG; Surgenor AE
    Bioorg Med Chem; 2006 Jul; 14(14):4792-802. PubMed ID: 16574416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
    Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
    J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.
    Li Y; Kim DJ; Ma W; Lubet RA; Bode AM; Dong Z
    J Chem Inf Model; 2011 Nov; 51(11):2904-14. PubMed ID: 21955044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.
    Foloppe N; Fisher LM; Francis G; Howes R; Kierstan P; Potter A
    Bioorg Med Chem; 2006 Mar; 14(6):1792-804. PubMed ID: 16289938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
    Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome.
    Vidović D; Muskal SM; Schürer SC
    J Chem Inf Model; 2012 Dec; 52(12):3107-15. PubMed ID: 23121521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
    Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1.
    Comess KM; Trumbull JD; Park C; Chen Z; Judge RA; Voorbach MJ; Coen M; Gao L; Tang H; Kovar P; Cheng X; Schurdak ME; Zhang H; Sowin T; Burns DJ
    J Biomol Screen; 2006 Oct; 11(7):755-64. PubMed ID: 16956998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
    Chen XM; Lu T; Lu S; Li HF; Yuan HL; Ran T; Liu HC; Chen YD
    J Mol Model; 2010 Jul; 16(7):1195-204. PubMed ID: 20020310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.
    Huang X; Cheng CC; Fischmann TO; Duca JS; Richards M; Tadikonda PK; Reddy PA; Zhao L; Siddiqui MA; Parry D; Davis N; Seghezzi W; Wiswell D; Shipps GW
    Bioorg Med Chem Lett; 2013 May; 23(9):2590-4. PubMed ID: 23535330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the CHK1 allosteric inhibitor binding site.
    Vanderpool D; Johnson TO; Ping C; Bergqvist S; Alton G; Phonephaly S; Rui E; Luo C; Deng YL; Grant S; Quenzer T; Margosiak S; Register J; Brown E; Ermolieff J
    Biochemistry; 2009 Oct; 48(41):9823-30. PubMed ID: 19743875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel molecular probes of the Rio1 atypical protein kinase.
    Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
    Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
    Dar AC; Shokat KM
    Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors.
    Chen X; Liu H; Xie W; Yang Y; Wang Y; Fan Y; Hua Y; Zhu L; Zhao J; Lu T; Chen Y; Zhang Y
    J Chem Inf Model; 2019 Dec; 59(12):5244-5262. PubMed ID: 31689093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.
    Dixit A; Verkhivker GM
    J Chem Inf Model; 2012 Oct; 52(10):2501-15. PubMed ID: 22992037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of inhibitors of checkpoint kinase 1 through template screening.
    Matthews TP; Klair S; Burns S; Boxall K; Cherry M; Fisher M; Westwood IM; Walton MI; McHardy T; Cheung KM; Van Montfort R; Williams D; Aherne GW; Garrett MD; Reader J; Collins I
    J Med Chem; 2009 Aug; 52(15):4810-9. PubMed ID: 19572549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.
    Lv M; Ma S; Tian Y; Zhang X; Lv W; Zhai H
    Mol Biosyst; 2015 Jan; 11(1):275-86. PubMed ID: 25372494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.